Mesenchymal stem cells: Paradoxes of passaging

被引：591

作者：

Javazon, EH ^{[1
]}

Beggs, KJ ^{[1
]}

Flake, AW ^{[1
]}

机构：

[1] Childrens Hosp Philadelphia, Childrens Inst Surg Sci, Philadelphia, PA 19104 USA

来源：

EXPERIMENTAL HEMATOLOGY | 2004年 / 32卷 / 05期

关键词：

D O I：

10.1016/j.exphem.2004.02.004

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

The field of stem cell biology continues to evolve with the ongoing characterization of multiple types of stem cells with their inherent potential for experimental and clinical application. Mesenchymal stem cells (MSC) are one of the most promising stem cell types due to their availability and the relatively simple requirements for in vitro expansion and genetic manipulation. Multiple populations described as "MSCs" have now been isolated from various tissues in humans and other species using a variety of culture techniques. Despite extensive in vitro characterization, relatively little has been demonstrated regarding their in vivo biology and therapeutic potential. Nevertheless, clinical trials utilizing MSCs are currently underway. The aim of this review is to critically analyze the field of MSC biology, particularly with respect to the current paradox between in vitro promise and in vivo efficacy. It is the authors' opinion that until this paradox is better understood, therapeutic applications will remain limited. (C) 2004 International Society for Experimental Hematology. Published by Elsevier Inc.

引用

收藏

页码：414 / 425

页数：12

相关论文

共 189 条

[1]

Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure [J].

Abkowitz, JL ;

Robinson, AE ;

Kale, S ;

Long, MW ;

Chen, J .

BLOOD, 2003, 102 (04) :1249-1253

[2]

RECIPIENT ORIGIN OF BONE MARROW-DERIVED FIBROBLASTIC STROMAL CELLS DURING ALL PERIODS FOLLOWING BONE-MARROW TRANSPLANTATION IN HUMANS [J].

AGEMATSU, K ;

NAKAHORI, Y .

BRITISH JOURNAL OF HAEMATOLOGY, 1991, 79 (03) :359-365

[3]

LacZ and interleukin-3 expression in vivo after retroviral transduction of marrow-derived human osteogenic mesenchymal progenitors [J].

Allay, JA ;

Dennis, JE ;

Haynesworth, SE ;

Majumdar, MK ;

Clapp, DW ;

Shultz, LD ;

Caplan, AI ;

Gerson, SL .

HUMAN GENE THERAPY, 1997, 8 (12) :1417-1427

[4]

Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice [J].

Angelopoulou, M ;

Novelli, E ;

Grove, JE ;

Rinder, HM ;

Civin, C ;

Cheng, LZ ;

Krause, DS .

EXPERIMENTAL HEMATOLOGY, 2003, 31 (05) :413-420

[5]

Anker PSI, 2003, HAEMATOLOGICA, V88, P845

[6]

Autologous mesenchymal stem cell-mediated repair of tendon [J].

Awad, HA ;

Butler, DL ;

Boivin, GP ;

Smith, FNL ;

Malaviya, P ;

Huibregtse, B ;

Caplan, AI .

TISSUE ENGINEERING, 1999, 5 (03) :267-277

[7]

Failure of adult marrow-derived stem cells to generate marrow stroma after successful hematopoietic stem cell transplantation [J].

Awaya, N ;

Rupert, K ;

Bryant, E ;

Torok-Storb, B .

EXPERIMENTAL HEMATOLOGY, 2002, 30 (08) :937-942

[8]

Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection [J].

Baddoo, M ;

Hill, K ;

Wilkinson, R ;

Gaupp, D ;

Hughes, C ;

Kopen, GC ;

Phinney, DG .

JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 89 (06) :1235-1249

[9]

Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium - Feasibility, cell migration, and body distribution [J].

Barbash, IM ;

Chouraqui, P ;

Baron, J ;

Feinberg, MS ;

Etzion, S ;

Tessone, A ;

Miller, L ;

Guetta, E ;

Zipori, D ;

Kedes, LH ;

Kloner, RA ;

Leor, J .

CIRCULATION, 2003, 108 (07) :863-868

[10]

Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo [J].

Bartholomew, A ;

Patil, S ;

Mackay, A ;

Nelson, M ;

Buyaner, D ;

Hardy, W ;

Mosca, J ;

Sturgeon, C ;

Siatskas, M ;

Mahmud, N ;

Ferrer, K ;

Deans, R ;

Moseley, A ;

Hoffman, R ;

Devine, SM .

HUMAN GENE THERAPY, 2001, 12 (12) :1527-1541

← 1 2 3 4 5 6 7 8 9 10 →